31 reports of this reaction
3.4% of all BUTENAFINE HYDROCHLORIDE reports
#5 most reported adverse reaction
PRURITUS is the #5 most commonly reported adverse reaction for BUTENAFINE HYDROCHLORIDE, manufactured by Bayer Healthcare LLC.. There are 31 FDA adverse event reports linking BUTENAFINE HYDROCHLORIDE to PRURITUS. This represents approximately 3.4% of all 901 adverse event reports for this drug.
Patients taking BUTENAFINE HYDROCHLORIDE who experience pruritus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRURITUS is moderately reported among BUTENAFINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to pruritus, the following adverse reactions have been reported for BUTENAFINE HYDROCHLORIDE:
The following drugs have also been linked to pruritus in FDA adverse event reports:
PRURITUS has been reported as an adverse event in 31 FDA reports for BUTENAFINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRURITUS accounts for approximately 3.4% of all adverse event reports for BUTENAFINE HYDROCHLORIDE, making it a notable side effect.
If you experience pruritus while taking BUTENAFINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.